Bristol John W & Co. Inc. NY Sells 11,338 Shares of Johnson & Johnson $JNJ

Key Points

• Bristol John W & Co. Inc. NY sold 11,338 shares of Johnson & Johnson in the quarter, trimming its stake by 2.3% to 485,516 shares valued at about $90.02 million.
• Johnson & Johnson trades with a market cap of $584.24 billion and a 52‑week range of $141.50–$251.71, pays a $1.30 quarterly dividend (≈2.1% yield), and faces upbeat analyst sentiment (consensus target ≈ $235.91) alongside recent positives like FDA approval of the TECNIS PureSee lens and an EU label expansion request for Tecvayli.
• 69.55% institutional ownership — with large moves such as Norges Bank buying a new multi‑billion dollar stake and Vanguard holding 237 million shares — while insiders have sold ~30,142 shares (~$7.36M) in the last 90 days and now own 0.16% of the company.

Bristol John W & Co. Inc. NY lessened its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 485,516 shares of the company's stock after selling 11,338 shares during the quarter. Bristol John W & Co. Inc. NY's holdings in Johnson & Johnson were worth $90,024,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Norges Bank purchased a new stake in Johnson & Johnson during the 2nd quarter valued at $4,877,174,000. Laurel Wealth Advisors LLC increased its position in shares of Johnson & Johnson by 15,040.6% in the second quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company's stock valued at $1,133,512,000 after acquiring an additional 7,371,687 shares during the period. Capital International Investors raised its stake in shares of Johnson & Johnson by 545.6% during the third quarter. Capital International Investors now owns 3,865,050 shares of the company's stock valued at $716,657,000 after acquiring an additional 3,266,354 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Johnson & Johnson by 1.3% during the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company's stock valued at $36,209,060,000 after acquiring an additional 3,085,180 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Johnson & Johnson by 6.2% during the second quarter. Legal & General Group Plc now owns 18,917,274 shares of the company's stock worth $2,889,614,000 after purchasing an additional 1,097,855 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $242.43 on Friday. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $251.71. The stock's 50 day simple moving average is $231.22 and its two-hundred day simple moving average is $205.79. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The stock has a market cap of $584.24 billion, a price-to-earnings ratio of 21.94, a PEG ratio of 2.40 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion during the quarter. As a group, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.1%. Johnson & Johnson's dividend payout ratio (DPR) is currently 47.06%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approved the TECNIS PureSee intraocular lens for U.S. cataract patients — a commercial win for J&J’s Vision franchise that could drive incremental device sales and strengthen the company’s near-term revenue mix. Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens
• Positive Sentiment: Citigroup raised its price target to $274 and placed a Buy rating — a bullish analyst call that signals meaningful upside versus the current share level and may attract buyers. Benzinga
• Positive Sentiment: BofA increased its price target to $253 (from $227) citing pipeline growth while keeping a Neutral rating — the higher target and raised revenue assumptions reflect improving visibility on key drugs and support medium-term upside. BofA Raises Johnson & Johnson (JNJ) Price Target on Pipeline Growth
• Positive Sentiment: JNJ requested an EU label expansion for multiple myeloma drug Tecvayli based on phase III MajesTEC-9 data — approval would broaden indicated use and market opportunity in oncology. JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
• Positive Sentiment: Analyst commentary (Zacks) highlights J&J among names with strong business momentum despite macro headwinds — supportive narrative for investor confidence. The Zacks Analyst Blog: JPMorgan, Johnson & Johnson, Applied Materials and Value Line
• Neutral Sentiment: Coverage/narrative updates show modest fair‑value adjustments (e.g., fair value moved slightly to ~$237) as analysts rework individual drug assumptions — incremental but not game‑changing. How The Johnson & Johnson (JNJ) Narrative Is Shifting With Pipeline Rethinks And New Valuation Targets
• Neutral Sentiment: Barclays reaffirmed a Hold rating — keeps a portion of sell‑side sentiment cautious despite positive pipeline headlines. Barclays Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)
• Neutral Sentiment: J&J appears on lists of “safe” dividend aristocrats — supportive for income investors but unlikely to trigger large near‑term moves. Hope for the Best and Plan for the Worst: The 5 Safest Dividend Aristocrats

Insiders Place Their Bets

In related news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company's stock, valued at $5,598,700.17. This trade represents a 21.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Timothy Schmid sold 1,322 shares of the business's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,251,310.02. The trade was a 4.94% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 30,142 shares of company stock worth $7,360,528. Company insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on JNJ shares. Daiwa Securities Group boosted their price target on Johnson & Johnson from $203.00 to $237.00 and gave the company an "outperform" rating in a report on Thursday, January 29th. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $230.00 to $240.00 and gave the stock an "overweight" rating in a research report on Thursday, January 22nd. Rothschild & Co Redburn boosted their target price on Johnson & Johnson from $180.00 to $210.00 and gave the company a "neutral" rating in a research note on Thursday, February 19th. Morgan Stanley set a $262.00 price target on Johnson & Johnson and gave the stock an "overweight" rating in a research note on Wednesday, January 28th. Finally, Sanford C. Bernstein lifted their price target on shares of Johnson & Johnson from $208.00 to $225.00 and gave the company a "market perform" rating in a report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $235.91.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.